A phase I study of anti-BCMA CAR T cell therapy in relapsed/refractory multiple myeloma and plasma cell leukemia.

Chun-Rui LiWenyue CaoYimei QueQiuxiang WangYi XiaoChaojiang GuDi WangJue WangLijun JiangHao XuJinhuan XuXiaoxi ZhouZhenya HongNa WangLiang HuangShangkun ZhangLiting ChenXia MaoMin XiaoWei ZhangLi MengYang CaoTongcun ZhangJian LiJianfeng Zhou

Published in: Clinical and translational medicine (2022)

Anti-BCMA CAR T cell treatment is safe and highly active in R/R multiple myeloma.

Keyphrases

multiple myeloma
cell therapy
stem cells
mesenchymal stem cells
acute myeloid leukemia
bone marrow
single cell
acute lymphoblastic leukemia
combination therapy